ID   C125-PM
AC   CVCL_8175
AS   CVCL_8174
SY   C125PM; C125
DR   cancercelllines; CVCL_8175
DR   CancerTools; 151763
DR   Cell_Model_Passport; SIDM01541
DR   ColonAtlas; C125
DR   Cosmic; 948842
DR   Cosmic; 995376
DR   Cosmic; 1043799
DR   Cosmic; 1223130
DR   Cosmic; 1312290
DR   Cosmic; 1479601
DR   Cosmic; 2301957
DR   Cosmic; 2800565
DR   DepMap; ACH-001456
DR   ECACC; 12022909
DR   GEO; GSM1346862
DR   GEO; GSM1374420
DR   GEO; GSM1448181
DR   IARC_TP53; 21746
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54807840
DR   Ximbio; 151763
RX   PubMed=10737795;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=29101300;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Unspecified (DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>C); ClinVar=VCV000375965; Zygosity=Unspecified (PubMed=20570890; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=16418264).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): ECACC; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11,14
ST   D13S317: 11,12
ST   D16S539: 9
ST   D21S11: 28
ST   D5S818: 9
ST   D7S820: 8,10 (PubMed=25926053)
ST   D7S820: 8.2,10 (ECACC)
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C5105; Colorectal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//